Prepare for the next guideline, label, or coverage decision
A P&T meeting, a coverage reconsideration, an HTA submission, or a label negotiation has a date set by someone else. The guideline, label, and coverage policy behind the claim you are bringing can move before it. Choose the question or preparation task below. Each guide says what to check, who needs it, and what an earlier or later date changes.
What to check before your date
-
FDA approval, NCCN guidelines, and payer coverage: three separate decisions
How oncology market access teams distinguish label approval, guideline inclusion, and payer coverage, and prepare when their dates diverge.
-
CMS and NICE timelines: decision dates and implementation windows
Distinguish CMS national coverage review milestones from NICE technology appraisal funding windows when planning evidence and implementation work.
-
What is a PDUFA date? Plan for approval, a CRL, or an extension
A PDUFA date is FDA's target for acting on a drug or biologic application. What approval, a CRL, an extension or a missed date means for a launch or deal plan.
-
NICE scheduled dates: plan for publication, a delay, or a suspension
What an expected NICE publication date commits NICE to, which outcomes a UK launch or access plan must cover, and where NICE's own record confirms the action.
-
When the guideline or label behind your claim moves before your date
How a written claim loses the guideline, label, or coverage policy under it, with a dated worked example and the seven-question check to run before your date.
-
When a guideline, label, or coverage change is delayed
Distinguish missing evidence, procedural delay, a different action, and an outcome after the deadline when an institutional change does not arrive.
-
GLP-1 coverage changes: start with the indication and the plan
A guide for market access and payer teams comparing GLP-1 coverage by indication, population, benefit, and effective date, with historical evidence examples.
What to bring to the review
-
Evidence preparation before a P&T or HTA deadline
What market access, HEOR, and medical affairs teams can prepare twelve, six, or three months before a committee or submission deadline.
-
Taking a claim into a coverage or P&T review
The restriction's population, comparator, and outcomes against today's record, the usual shapes of the gap between restriction and evidence, and the three-item packet that gets a decision rather than a deferral.
-
Label expansion readiness: planning for a new indication
A preparation guide for regulatory, launch, and market access teams assessing a possible label expansion and an earlier or later decision date.
Following a decision through the record
-
FDA approval is not clinical adoption
An approval or a positive trial is one gate. Map the chain that decides who can receive the therapy, and the four conditions that turn a result into an inflection.
-
What actually causes a medical guideline to change
A guideline change looks like a verdict on evidence. More often it turns on a model, a committee vote, and a waiting room.
-
From published evidence to standard of care: why timing varies
Two positive trials can reach a guideline in similar time and reach patients years apart. The difference is the number and shape of the gates.
-
The anatomy of a clinical consensus reversal
A reversal has four parts: a position, an evidence event, a set of institutional responses, and a test of what survived.
How the decisions are ordered
-
How evidence becomes a decision
How guideline, label, and coverage decisions are ordered, and which of them a forecast is registered against.